Dr. Burstein on Adjuvant Endocrine Therapy for ER+ Breast Cancer

Harold Burstein, MD, PhD
Published: Tuesday, May 09, 2017



Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with estrogen receptor (ER)-positive breast cancer.

Adjuvant endocrine therapy is the standard for most women who have ER-positive early stage breast cancer. But, for postmenopausal women with ER-positive breast cancer, treatment has historically been tamoxifen or an aromatase inhibitor. Aromatase inhibitors have been shown to have a slight advantage, says Burstein, specifically in women who have higher-risk biologies.

Anti-estrogen therapy remains a critical therapy for postmenopausal women with ER-positive breast cancer, and progress is being made regarding drug selection and duration of treatment, Burstein adds.
 


Harold J. Burstein, MD, PhD, senior physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses adjuvant endocrine therapy for postmenopausal women with estrogen receptor (ER)-positive breast cancer.

Adjuvant endocrine therapy is the standard for most women who have ER-positive early stage breast cancer. But, for postmenopausal women with ER-positive breast cancer, treatment has historically been tamoxifen or an aromatase inhibitor. Aromatase inhibitors have been shown to have a slight advantage, says Burstein, specifically in women who have higher-risk biologies.

Anti-estrogen therapy remains a critical therapy for postmenopausal women with ER-positive breast cancer, and progress is being made regarding drug selection and duration of treatment, Burstein adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x